<?xml version="1.0" encoding="UTF-8"?>
<p>Cao 
 <italic>et al</italic>.[
 <xref rid="j_jtim-2019-0012_ref_027" ref-type="bibr">27</xref>] found that high-dose corticosteroid therapy (&gt; 150 mg/d methylprednisolone or equivalent) significantly increased both 30-day and 60-day mortality, whereas no significant impact was observed for low-to-moderate doses of corticosteroids (25–150 mg/d methylprednisolone or equivalent). Li 
 <italic>et al</italic>.[
 <xref rid="j_jtim-2019-0012_ref_028" ref-type="bibr">28</xref>] found that patients with PaO2/ FiO2 &lt; 300 mm Hg, low-to-moderate-dose corticosteroid treatment significantly reduced both 30-day mortality and 60-day mortality. For patients with PaO2/FiO2 ≥ 300 mm Hg, corticosteroids (irrespective of dose) showed no benefits and even increased 60-day mortality.
</p>
